Ocugen Future Growth
Future criteria checks 0/6
Ocugen is forecast to grow earnings and revenue by 29.6% and 61.3% per annum respectively while EPS is expected to grow by 29.1% per annum.
Key information
29.6%
Earnings growth rate
29.1%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | 61.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 21 | -61 | N/A | N/A | 1 |
12/31/2025 | N/A | -73 | N/A | N/A | 1 |
12/31/2024 | N/A | -67 | N/A | N/A | 3 |
12/31/2023 | N/A | -69 | N/A | N/A | 3 |
9/30/2023 | N/A | -76 | -77 | -68 | N/A |
6/30/2023 | N/A | -83 | -76 | -68 | N/A |
3/31/2023 | N/A | -80 | -69 | -63 | N/A |
12/31/2022 | N/A | -81 | -65 | -60 | N/A |
9/30/2022 | N/A | -74 | -59 | -56 | N/A |
6/30/2022 | N/A | -63 | -52 | -50 | N/A |
3/31/2022 | N/A | -69 | -59 | -58 | N/A |
12/31/2021 | N/A | -58 | -49 | -48 | N/A |
9/30/2021 | N/A | -48 | -41 | -39 | N/A |
6/30/2021 | N/A | -47 | -35 | -34 | N/A |
3/31/2021 | 0 | -38 | -16 | -15 | N/A |
12/31/2020 | 0 | -34 | -15 | -15 | N/A |
6/30/2020 | 0 | -30 | -19 | -19 | N/A |
3/31/2020 | N/A | -18 | -19 | -19 | N/A |
12/31/2019 | N/A | -20 | -17 | -17 | N/A |
9/30/2019 | N/A | -39 | -11 | -11 | N/A |
6/30/2019 | N/A | -18 | -12 | -12 | N/A |
3/31/2019 | N/A | -19 | -12 | -12 | N/A |
12/31/2018 | N/A | -18 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2H51 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2H51 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2H51 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2H51 is forecast to have no revenue next year.
High Growth Revenue: 2H51 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2H51's Return on Equity is forecast to be high in 3 years time